Clinical Trials Logo

Dementia clinical trials

View clinical trials related to Dementia.

Filter by:

NCT ID: NCT03514095 Active, not recruiting - Dementia Clinical Trials

Cognitive Stimulation in the Elderly: Individual Intervention on Cognitive Frailty

ECOG_CS
Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Cognitive Stimulation (CS) in the elderly, as a group intervention, shows benefits on the cognition and quality of life of people with neurocognitive disorder (NCD)(ie, dementia). The evidence of cognitive stimulation as an individualized intervention, conducted at home, by the caregiver is limited. The main objective of this trial is to evaluate the effectiveness of the Individual Cognitive Stimulation Therapy program - "Making a Difference 3 - individual Cognitive Stimulation Therapy (MD3), its acceptability and applicability by the dyad (people with NCD and their caregiver) in the Portuguese population. To achieve this purpose a pilot study will be conducted (randomized control trial), with two moments of evaluation - before the intervention of individual cognitive stimulation and after the intervention in both groups (Group 1 - group subject to intervention: individual cognitive stimulation program called "MD3"; Group 2 - group subject to usual care).The investigators intend to know the effect of the program on cognitive domains, quality of life and relationship between caregiver and care recipient. And, as well as understand the acceptability and applicability of the program by participants (dyad).

NCT ID: NCT03496675 Active, not recruiting - Depression Clinical Trials

Music Interventions for Dementia and Depression in Elderly Care

MIDDEL
Start date: July 18, 2018
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness of two music-based approaches - group music therapy and recreational choir singing - for reducing depression symptoms in people living with dementia. It also examines mechanisms and heterogeneity of treatment effects.

NCT ID: NCT03441516 Active, not recruiting - Alzheimer's Disease Clinical Trials

Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia

ALFO-AD
Start date: April 19, 2018
Phase: Phase 4
Study type: Interventional

This study will evaluate the performance of Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) in patients with Alzheimer's disease (AD).

NCT ID: NCT03430401 Active, not recruiting - Clinical trials for Mild Cognitive Impairment

Computer-based Cognitive Rehabilitation Program for Healthy Older Adults, Older People With Mild Cognitive Impairment and Mild Dementia

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

This study will adopt a newly developed computer-based cognitive rehabilitation program targeting the encoding stage of memory. The aims of the study are: 1. To test the feasibility of conducting a newly developed computer-based cognitive rehabilitation program for healthy older adults, people with MCI and mild dementia. 2. To test the effectiveness of the newly developed program in improving cognitive function and enabling maintenance of occupational performance in healthy older adults, people with MCI or mild dementia. Using an iPad application, study participants will learn a memory encoding strategy to support completion of their daily activities. By implementing memory encoding strategies during the mild stages of cognitive decline, the project aims to prolong independence in functional performance. It is anticipated that adoption of the same memory strategies will enable maintain performance as they may experience ongoing cognitive decline.

NCT ID: NCT03419039 Active, not recruiting - Clinical trials for Coronary Artery Disease

Anthocyanins as Dementia Prevention?

ACID
Start date: January 5, 2018
Phase: N/A
Study type: Interventional

The aim of this project is to study the safety and efficacy of anthocyanins in improving key dementia-related mechanisms and cognitive functioning in older people at risk for dementia. Secondary analyses will include a variety of biological measures, including biochemistry, imaging and cardiovascular measures.

NCT ID: NCT03405675 Active, not recruiting - Depression Clinical Trials

Gerontology Research Programme: The Singapore Longitudinal Ageing Studies (SLAS I & II)

SLAS
Start date: July 1, 2003
Phase:
Study type: Observational

The Gerontology Research Programme (GRP) in the National University Singapore's Department of Psychological Medicine, was formed to coordinate and facilitate the conduct of multi-disciplinary research on in a wide range of research on ageing and health. The establishment of the Singapore Longitudinal Aging Cohort will provide a large community-based cohort of elderly subjects for observational studies with useful clinical applications. Research synergy is achieved in terms of pooling multi-disciplinary expertise, and combining genetic, biological, environmental, behavioural, social, clinical, and health services approaches to gerontological research.

NCT ID: NCT03403257 Active, not recruiting - Dementia Clinical Trials

Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)

BASIC-C
Start date: April 11, 2018
Phase:
Study type: Observational

The Mexican American population in the U.S. is rapidly growing and aging. This project seeks to determine the prevalence and outcomes of cognitive impairment and dementia in Mexican Americans. It also seeks solutions to help patients with cognitive impairment and dementia and their caregivers get the resources they need.

NCT ID: NCT03370796 Active, not recruiting - Dementia Clinical Trials

Group Reminiscence Therapy for Elderly People With Cognitive Decline in Institutional Context

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

The project presented here respond to this emerging need by implementing a Reminiscence Therapy program dedicated to elderly people in an institutional context. This will be a multicenter, randomized controlled study in which the participants' allocation will be made without their knowledge. Before the randomization process, the screening evaluation will be done, which will allow to verify the presence of the inclusion and exclusion criteria. The target population will be people age 65 or above years who present cognitive decline. After the randomization process, participants will be allocated randomly in the experimental group where the reminiscence program (composed by a main strand and maintenance strand) or in the usual institutional care group. The evaluation of the participants will be carried out individually and will take place in four different moments.This study will be conducted in RSE in the central region of Portugal.

NCT ID: NCT03260920 Active, not recruiting - Clinical trials for Frontotemporal Dementia

Intranasal Oxytocin for Frontotemporal Dementia

FOXY
Start date: January 31, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick's disease. This study will take place in approximately 15 centres across Canada and the United States. Approximately 112 patients in total will be enrolled in this study. In the first phase we will examine which of three different dosing schedules of oxytocin may be more effective. In the second phase of the study, patients entering the study will be randomized to the oxytocin dosing schedule that appeared most effective in the first phase.

NCT ID: NCT03234686 Active, not recruiting - Clinical trials for Mild Cognitive Impairment

Deferiprone to Delay Dementia (The 3D Study)

Start date: January 19, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase 2, randomised, placebo-controlled, multicentre study to investigate the safety and efficacy of Deferiprone in participants with Prodromal Alzheimer's Disease (pAD) and Mild Alzheimer's Disease (mAD). In this phase 2 study, the investigators aim to determine whether Deferiprone (15 mg/kg BID orally) slows cognitive decline in Alzheimer's patients. As secondary outcomes, safety and iron levels in the brain will be evaluated.